News Releases

Corvidia Therapeutics to Participate in Jefferies 2019 London Healthcare Conference and Stifel Healthcare Conference 2019

Waltham, Mass., November 18, 2019—Corvidia Therapeutics Inc., a clinical stage company focused on the research, development and commercialization of transformative therapies in cardio-renal disease, today announced the company will present at two upcoming healthcare conferences. Executives will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 7:20 a.m. – 7:50 a.m. GMT / 2:20 a.m. – 2:50 a.m. ET and the Stifel Healthcare Conference 2019 in New York City on Wednesday, November 20 at 9:10 a.m. – 9:40 a.m. ET.

November 18th, 2019

DOWNLOAD NOW

Corvidia Therapeutics to Present New Data at the American Heart Association’s Scientific Sessions 2019

Waltham, MA, November 14, 2019 — Corvidia Therapeutics, a clinical stage company focused on the research, development and commercialization of transformative therapies in cardio-renal disease, will present at the American Heart Association’s (AHA) annual scientific sessions in Philadelphia, Pennsylvania. The Company will release new Phase 1 clinical data on its lead asset, ziltivekimab, being developed to be to reduce inflammation for the purpose of reducing major adverse cardiovascular events in CKD patients. It will also release new nonclinical data on IL-6, suggesting a specific genotype variation may predict the impact of inflammation on cardiovascular events in patients with cardiovascular disease.

November 14th, 2019

DOWNLOAD NOW

Corvidia Therapeutics to Present New Data at ASN Kidney Week 2019

Waltham, MA, November 6, 2019 — Corvidia Therapeutics, a clinical stage company focused on the research, development and commercialization of transformative therapies in cardio-renal disease, will deliver two key presentations at the American Society of Nephrology’s annual meeting in Washington D.C. Both presentations will release new data on Corvidia’s lead asset, ziltivekimab, being developed to be the first therapy to reduce inflammation for the purpose of reducing major cardiovascular events in CKD patients.

November 6th, 2019

DOWNLOAD NOW

Corvidia Therapeutics Initiates Phase 2b Dose-Finding Study for Ziltivekimab

Waltham, MA, June 13, 2019 — Corvidia Therapeutics Inc., a clinical stage biotechnology company, announced today the initiation of patient screening for a Phase 2b dose-finding study of ziltivekimab. Previously known as COR-001, ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD).

June 13th, 2019

DOWNLOAD NOW

Corvidia Therapeutics to Participate in 2019 Jefferies Global Healthcare Conference

Corvidia Therapeutics Inc., a clinical stage biotechnology company, today announced Marc de Garidel, chief executive officer will present in the Jefferies 2019 Global Healthcare Conference in New York City on Friday, June 7 at 9:30 am.

June 4th, 2019

DOWNLOAD NOW

Corvidia Therapeutics Announces Dr. Preston Klassen Joins its Board of Directors

Corvidia Therapeutics Inc., a clinical stage biotechnology company, today announced the appointment of Dr. Preston Klassen, M.D., M.H.S. to its Board of Directors…

May 21st 2019

DOWNLOAD NOW

Corvidia Therapeutics Secures $60 Million in Series B Funding

Corvidia Therapeutics secures $60 million in series B funding to accelerate clinical work starting with 25th of April 2018…

APR 25TH 2018

DOWNLOAD NOW

Corvidia Therapeutics Appoints Marc de Garidel as Chief Executive Officer

Marc de Garidel was appointed Chief Executive Officer at Corvidia Therapeutics starting with 29th of March 2018…

MAR 29TH 2018

DOWNLOAD NOW

Sylvie Gregoire Appointed as Chair of the Board of Directors

Sylvie Gregoire is Appointed as Chair of the Board of Directors at Corvidia Therapeutics starting with the 14th of June 2016…

JUN 14TH 2016

DOWNLOAD NOW

Corvidia Therapeutics Raises 26M Series a Financing

Corvidia Therapeutics announces the milestone of raising 26m series a financing starting with the 16th of February 2016…

FEB 16TH 2016

DOWNLOAD NOW
Our Latest News Releases

Contact Us

Contact Corvidia

35 Gatehouse Drive
Waltham, MA 02451
Tel: +1-781-205-4755

Media Contact

Media Contact information

McDougall Communications on behalf of Corvidia TX
Elizabeth Harness
Tel: +1 (585) 441-0202